Jakavi approved in Korea

Novartis Korea has recently received approval from the Korea Food and Drug Administration for Jakavi (INC424, ruxolitinib tablets), a drug for the treatment of disease-related splenomegaly and/or its associated symptoms in adult patients with myelofibrosis (MF), a blood cancer.1 Jakavi is the first antineoplastic agent indicated for this patient population.

Jakavi, an oral inhibitor of the J...